Compare CVNA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | IQV |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Other Specialty Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8B | 27.7B |
| IPO Year | 2017 | 2013 |
| Metric | CVNA | IQV |
|---|---|---|
| Price | $314.97 | $171.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 16 |
| Target Price | ★ $436.13 | $230.56 |
| AVG Volume (30 Days) | ★ 3.3M | 2.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 431.45 | 4.67 |
| EPS | ★ 8.45 | 7.84 |
| Revenue | ★ $20,322,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.43 | $5.85 |
| P/E Ratio | $36.28 | ★ $20.98 |
| Revenue Growth | ★ 48.63 | 41.60 |
| 52 Week Low | $148.25 | $134.65 |
| 52 Week High | $486.89 | $247.05 |
| Indicator | CVNA | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 42.33 |
| Support Level | $289.33 | $156.43 |
| Resistance Level | $358.58 | $193.26 |
| Average True Range (ATR) | 17.03 | 6.29 |
| MACD | 1.78 | 1.36 |
| Stochastic Oscillator | 43.06 | 38.39 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.